Senior Manager MedTech Surgery
About the job
- A bachelor's degree in Computer Science, Information Systems, Engineering, or Business is required.
- At least 8 years of technology leadership experience, including direct experience leading line-of-business, engineering, data operations, or product teams, and at least 6 years of people leadership at scale in matrixed environments.
- Ability to apply technology to solve business problems and partner with senior stakeholders.
- Experience with business processes such as bids and tenders, order to cash, and customer engagement, and their interfaces with foundational technology platforms such as enterprise resource planning, customer relationship management, and manufacturing execution systems.
- Experience in product management, agile delivery, and portfolio governance, with the ability to connect roadmaps to measurable outcomes.
- Fluency with cloud, application programming interfaces, data platforms, analytics, artificial intelligence, machine learning, and generative AI, and hands-on leadership implementing these capabilities beyond pilot stages.
- Experience modernizing legacy environments while safely and compliantly introducing new digital and AI-enabled solutions.
- Ability to influence decisions across a complex, matrixed organization to drive alignment, deliver scalable solutions, and advance strategic priorities supporting business and regional needs.
- Co-create the regional Surgery technology strategy in alignment with MedTech business goals and translate it into a prioritized multi-year product and platform roadmap with clear value outcomes.
- Develop technology as a competitive advantage by accelerating innovation, simplification, and go-to-market agility across priority markets and franchises.
- Serve as a strategic technology partner to regional senior leaders, jointly identifying opportunities and advising on technology transformation and application to support growth, efficiency, and customer and patient experience.
- Provide accountable technology leadership for end-to-end business-unit outcomes, aligning strategy, platforms, and execution across the regional value chain.
- Develop compliant technology in partnership with functions such as Cybersecurity, Regulatory Affairs, and Legal Affairs.
- Build cross-region partnerships to leverage technology efforts and accelerate regional process digitalization.
- Operationalize artificial intelligence, machine learning, and generative AI, including responsible AI, across commercial, supply chain, service, and research-and-development-adjacent use cases, including pricing and tenders, sales aids, demand sensing, customer segmentation and targeting, revenue growth analysis, digital assistance for healthcare-professional engagement, intelligent service, computer vision for quality, and workflow automation, grounded in robust data governance and security.
- Use data and analytics to deliver actionable insights across countries and functions; champion interoperable data platforms, real-time telemetry from connected devices, and privacy-by-design practices.
- Drive a disciplined high-performing-team product management approach to ideate, build, and scale high-impact solutions; link roadmaps to clear objectives and key results and dependable delivery.
- Own the regional business technology portfolio, including prioritization, funding, delivery, adoption, and benefits realization, leveraging global product teams and platforms.
- Lead and develop a high-performing team of product, engineering, data, and delivery leaders; attract talent, foster an inclusive learning-oriented culture, promote retention, and support continuous team growth and development.
- Curate outside-in innovation and strategic partnerships with technology providers, governments, and advisory boards to shape policies and deliver outcomes.
- Coach and support people managers to lead effectively and build inclusive, high-engagement cultures within their teams.
- Develop and manage a fit-for-purpose regional technology budget, aligning investment decisions with value, risk, and compliance and optimizing run versus change.
- Uphold quality, cybersecurity, privacy, and compliance expectations for MedTech software and services in partnership with Quality/Regulatory, Legal, and Privacy teams.
- Ensure technology enables successful regional product launches and lifecycle management, tailoring solutions to local market dynamics and care pathways.
- Champion customer-centric design with providers, payers, and health systems; translate healthcare professional and patient needs into product requirements for platform and workflow innovation.
- Coordinate customer engagement on technology matters such as connectivity, cybersecurity, and privacy, and contribute to building technology capabilities and strengthening technology skills of commercialization teams.
- MedTech Surgery domain exposure, such as digital surgery and robotics, imaging and computer vision, or connected capital equipment.
- Experience working with clinical, commercial, and supply chain stakeholders across multi-country regional footprints.
- Success hiring and developing technical and product talent, with executive presence and change leadership.
About the company
Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
- Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
- Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.
What critics are saying
- Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
- Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
- Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.
What makes Johnson & Johnson unique
- Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
- Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
- Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
-2%1 year growth
-2%2 year growth
-2%Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.
US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.
Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.
Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.
Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.